Medpace Holdings, Inc.
MEDP Large CapHealthcare · Diagnostics & Research
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocard
Medpace Holdings, Inc. Stock at a Glance
Medpace Holdings, Inc. (MEDP) is currently trading at $467.34 with a market capitalization of $13.3B. The trailing P/E ratio stands at 29.41x, with a forward P/E of 25.18x. The 52-week range spans from $294.07 to $628.92; the current price is 25.7% below the yearly high. Year-over-year revenue growth stands at +26.5%. The net profit margin stands at 17.19%.
💰 Dividend
Medpace Holdings, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
12 analysts rate Medpace Holdings, Inc. (MEDP) on consensus: Hold. The average price target is $442.83, implying -5.24% from the current price. Analyst price targets range from $329.00 to $495.00.
Medpace Holdings, Inc.: The Investment Case in Detail
Medpace Holdings, Inc. (MEDP) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Top-line momentum is unusually strong with revenue expanding 26.5% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 71.9%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 77.25% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
What to Watch Next
- The forward P/E of 25.18x is meaningfully below the trailing 29.41x — analysts expect earnings to step up; the next earnings release is the test.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 26.5% YoY
- High return on equity (77.25% ROE)
- High gross margin of 71.9% — indicates pricing power
- Solid balance sheet with low debt (D/E 24.42)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to market-like volatility, elevated short interest (8.93%).
Trading Data
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Medpace Holdings, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news